ANAkie Nakamura

Akie Nakamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akie Nakamura has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeted long-read sequencing reveals allele-specific methylation profiles at the GNAS locus in pseudohypoparathyroidism with various etiologies

    by Sayuri Nakamura, Hiromune Narusawa, Tatsuki Urakawa, Yukie Tanimoto, Kyoichiro Tsuchiya, Taro Shimamoto, Takahiro Mochizuki, Jun Mori, Kensuke Shoji, Sayaka Kawashima, et al.

    Patients with pseudohypoparathyroidism (PHP) show PTH resistance due to reduced Gsα expression. Loss-of-function variants in maternal Gsα-coding exons cause PHP type 1A (PHP1A), and methylation defects in GNAS-differentially methylated regions (DMRs) at the GNAS locus cause PHP type 1B (PHP1B). The GNAS-AS1:TSS-DMR (AS1-DMR), GNAS-AS2:TSS-DMR (AS2-DMR), GNAS-XL:Ex1-DMR (XL-DMR), and GNAS-A/B:TSS-DMR (A/B-DMR) are maternally methylated. The GNAS-NESP:TSS-DMR (NESP-DMR) is paternally methylated. STX16 functions as a long-range enhancer for NESP55 and XL. PHP1B cases commonly exhibit hypomethylated A/B-DMR and various methylation patterns in other GNAS-DMRs; however, the regulatory mechanisms for methylation patterns in GNAS-DMRs remain unclear. We evaluated allele-specific methylation levels for all CpGs within the GNAS locus together with structural abnormalities using targeted long-read sequencing (T-LRS) in a PHP1A case with a deletion affecting the 3′ side A/B-DMR to GNAS exon 1, 8 PHP1B cases (3 familial cases [maternal STX16 deletion, maternal GNAS duplication, and retrotransposon insertion on the maternal allele], a sporadic case with STX16 deletion, and 4 epimutation cases [2 typical and 2 atypical methylation patterns]), and an individual with paternal GNAS duplication showing normal phenotype. The PHP1A case showed normal methylation at the intact A/B-DMR, narrowing the critical region for the establishment and/or maintenance of the maternal methylation imprint in the A/B-DMR. The case with STX16 deletion and the case with maternal duplication causing elongation of the distance between STX16 and the AS2-DMR showed hypomethylated AS2-DMR, suggesting the incomplete enhancer effect of STX16 on the AS2-DMR. Furthermore, we detected the precise region of the AS2-DMR. The case with retrotransposon insertion (chr20:58 863 683) showed markedly hypomethylated A/B-DMR, plus mild hypomethylation of the AS1-DMR, AS2-DMR, and XL-DMR, undetected by conventional methylation analyses. Sporadic cases exhibited mosaic methylation abnormalities in all GNAS-DMRs, indicating that abnormal methylation occurred during early embryogenesis. Targeted-LRS is a powerful tool for clarifying methylation pattern regulation in GNAS-DMRs.

  • Open Access

    Endocrine disorders in pediatric medulloblastoma survivors treated with X-ray or proton beam therapy: a single-institution retrospective study

    by Naoya Kaneko, Shuntaro Morikawa, Megumi Endo, Nozomi Hishimura, Liu Zhitong, Takeshi Yamaguchi, Hisato Segoe, Jutaro Abe, Kazumi Oura, Saori Sawai, et al.

    Medulloblastoma, a common pediatric central nervous system disease, is managed with surgery, chemotherapy, and craniospinal irradiation (CSI) delivered with either X-rays or protons. Proton-beam CSI, introduced to protect the surrounding tissues, may reduce endocrine toxicity. In this single-institution retrospective observational study, we evaluated adverse endocrine events in 14 patients diagnosed with medulloblastoma before 13 years of age: 9 and 5 received X-ray and proton beam CSI, respectively. In the X-ray therapy group, the median age at diagnosis was 4.2 (range: 1.4–12.5) years, the median post-radiation follow-up was 19.5 (9.7–34.7) years, and the median CSI dose was 25.2 (23.4–36.0) Gy. The proton beam therapy group showed corresponding medians of 9.4 (5.3–11.7) years, 6.9 (5.4–8.1) years, and 23.4 (23.4–36.0) Gy. Five years after radiation therapy completion, the incidence of growth hormone deficiency was 44% (4/9) and 60% (3/5) in the X-ray and proton beam therapy groups, respectively. However, primary hypothyroidism and central hypothyroidism were exclusively observed in the X-ray therapy group, in 33% (3/9) and 11% (1/9) of patients. Given the short follow-up period for the proton beam therapy group, the difference in the occurrence rates of gonadal dysfunction and adrenal insufficiency is currently unknown. Our findings suggest that, at ≤5 years after the completion of radiation therapy, radiation-induced hypothyroidism was observed only in patients treated with X-ray therapy and not in those treated with proton beam therapy. Further studies with larger cohorts and longer follow-up periods are required to clarify this possible advantage and to refine radiation therapy protocols.

  • Open Access

    Associations between urinary phthalate metabolites and reproductive, adrenal, and gonadotropic hormones in peripubertal children: the Hokkaido study

    by Ayaka Yasuda, Yu Ait Bamai, Takeshi Yamaguchi, Rahel Mesfin Ketema, Yi Zeng, Megasari Marsela, Yoshinori Ikenaka, Akie Nakamura, Takeya Kitta, Masafumi Kon, et al.


  • Open Access

    Skin Reaction to Leuprorelin Acetate

    by Nozomi Hishimura, Naoya Kaneko, Akie Nakamura, Shuntaro Morikawa

  • Open Access

    Temple Syndrome: Comprehensive Clinical Study in Genetically Confirmed 60 Japanese Patients

    by Tomoe Ogawa, Hiromune Narusawa, Keisuke Nagasaki, Rika Kosaki, Yasuhiro Naiki, Michihiko Aramaki, Keiko Matsubara, Akie Nakamura, Maki Fukami, Tsutomu Ogata, et al.

    Objective: Temple syndrome (TS14) is a rare 14q32.2-related imprinting disorder. Here we report comprehensive clinical findings in TS14. Methods: We obtained detailed clinical findings in 60 Japanese patients with genetically confirmed TS14, using a questionnaire to attending physicians. The 60 patients consisted of 31 with maternal uniparental disomy 14 [UPD(14)mat], 22 with epimutation, 5 with deletions, and 2 with UPD(14)mat or epimutation. Results: Small for gestational age, postnatal (∼2 years of age) short stature, and central precocious puberty (CPP) were identified in 88.3%, 87.0%, and 86.0% of patients, respectively. GH therapy was performed in 32 patients, increasing the median height SD score for height from −3.4 to −2.4, and GnRH analog therapy was performed in 32 patients, ameliorating CPP. Furthermore, the survey showed intellectual and developmental disabilities in 21.6% of patients, neurodevelopmental disorders in 21.6% of patients, obesity in 20.0% of patients, hypercholesterolemia in 26.5% of patients aged ≥6 years, diabetes mellitus in 12.8% of patients aged ≥9 years, and Silver-Russell syndrome-like and/or Prader-Will syndrome-like phenotypes in 87.7% of patients in infancy. Notably, 42.9% of patients were enrolled in special classes in childhood, whereas 98.2% of patients attended college or had jobs in adulthood. Hypercholesterolemia and diabetes mellitus were observed before the development of obesity in a substantial fraction of TS14 patients and were controlled by oral medications in most affected patients. Conclusion: These results clarify the detailed clinical characteristics of TS14. On the basis of these findings, we propose an efficient diagnostic approach and pertinent clinical management for TS14 patients.


  • Open Access

    Risk assessment of assisted reproductive technology and parental age at childbirth for the development of uniparental disomy-mediated imprinting disorders caused by aneuploid gametes

    by Kaori Hara-Isono, Keiko Matsubara, Akie Nakamura, Shinichiro Sano, Takanobu Inoue, Sayaka Kawashima, Tomoko Fuke, Kazuki Yamazawa, Maki Fukami, Tsutomu Ogata, et al.

    Background: Our previous study suggested that assisted reproductive technology (ART) may be a possible risk factor for the development of epimutation-mediated imprinting disorders (epi-IDs) for mothers aged ≥ 30 years. However, whether ART or advanced parental age facilitates the development of uniparental disomy-mediated IDs (UPD-IDs) has not yet been investigated. Results: We enrolled 130 patients with aneuploid UPD-IDs including various IDs confirmed by molecular studies and obtained ART data of the general population and patients with epi-IDs from a robust nationwide database and our previous report, respectively. We compared the proportion of ART-conceived livebirths and maternal childbearing age between patients with UPD-IDs and the general population or patients with epi-IDs. The proportion of ART-conceived livebirths in patients with aneuploid UPD-IDs was consistent with that in the general population of maternal age ≥ 30 years and was lower than that in the patients with epi-IDs, although there was no significant difference. The maternal childbearing age of patients with aneuploid UPD-IDs was skewed to the increased ages with several cases exceeding the 97.5th percentile of maternal childbearing age of the general population and significantly higher than that of patients with epi-IDs (P < 0.001). In addition, we compared the proportion of ART-conceived livebirths and parental age at childbirth between patients with UPD-IDs caused by aneuploid oocytes (oUPD-IDs) and that by aneuploid sperm (sUPD-IDs). Almost all ART-conceived livebirths were identified in patients with oUPD-IDs, and both maternal age and paternal age at childbirth were significantly higher in patients with oUPD-IDs than in patients with sUPD-IDs. Because maternal age and paternal age were strongly correlated (rs = 0.637, P < 0.001), higher paternal age in oUPD-IDs was explained by the higher maternal age in this group. Conclusions: Different from the case of epi-IDs, ART itself is not likely to facilitate the development of aneuploid UPD-IDs. We demonstrated that advanced maternal age can be a risk factor for the development of aneuploid UPD-IDs, particularly oUPD-IDs.


  • Long-term Effect of Aromatase Inhibition in Aromatase Excess Syndrome

    by Gerhard Binder, Akie Nakamura, Roland Schweizer, Tsutomu Ogata, Maki Fukami, Keisuke Nagasaki

    Context Aromatase excess syndrome (AEXS) is a very rare disorder characterized by prepubertal gynecomastia, bone age acceleration, and early growth arrest. Heterozygote submicroscopic rearrangements within the promotor of CYP19A1 result in overexpression of aromatase and enhanced aromatization of androgens. Objective The objective was to study long-term treatment effects of an aromatase inhibitor. Methods Data from 7 boys with AEXS were retrospectively collected. Genetic analysis revealed upstream of CYP19A1 a 165 901 bp deletion in 4 German cousins, a 198 662 bp deletion in 2 Japanese brothers, and a 387 622 bp tandem duplication in a Japanese boy. Results All boys developed prepubertal gynecomastia, at median 9.0 years of age (range: 7.0-11.0). Height was +1.20 standard deviation score (SDS) (–0.24 to +1.98); predicted adult height was -1.29 SDS (-3.29 to +1.09). Four boys were treated with 1.0 mg of anastrozole daily, while 3 reached adult height untreated. Treatment with anastrozole was stopped after 5.6 years (4.0-6.8). Three treated boys exceeded their prognosis by 2.4, 6.9, and 8.1 cm, while 1 untreated boy fell below the prognosis by 8.6 cm. One treated with a low dose and 2 untreated reached their prognosis. Adult heights were –0.91 SDS with anastrozole (–2.86 to –0.29) and –0.15 SDS without (–2.31 to –0.03). Distance to target height was –0.22 SDS with anastrozole (–1.72 to +0.52) and +0.54 SDS without (+0.23 to +1.30). Conclusion Spontaneous growth in AEXS varied, even in the same family. Our data suggest that early started, long-term inhibition by anastrozole promotes adult height in boys with AEXS.


  • Successful kidney transplantation in a patient with neonatal‐onset ILNEB

    by Takayuki Okamoto, Akie Nakamura, Asako Hayashi, Takeshi Yamaguchi, Yayoi Ogawa, Ken Natsuga, Kumiko Yanagi, Kiyohiko Hotta

    Background: ILNEB constitute an autosomal recessive disorder caused by homozygous or compound heterozygous mutation of the gene for the ITGA3. To date, 8 ILNEB patients have been reported, but all 6 neonatal‐onset ILNEB patients suffered early death within 2 years. The most common cause of death among previously reported ILNEB patients was exacerbation of the respiratory condition.Methods: In this study, we describe a case of ILNEB with neonatal onset in a female patient and the genetic and histopathological testing performed.Results: Our patient had a compound heterozygous mutation in ITGA3. Compared to previously reported patients, this patient exhibited milder clinical and histopathological characteristics. After experiencing a life‐threatening respiratory infection at 8 months old, the patient started periodic subcutaneous immunoglobulin treatment once every 1‐2 weeks for nephrotic‐range proteinuria‐induced secondary hypogammaglobulinemia. At the age of 3 years, proteinuria gradually increased with severe edema despite strict internal management. Therefore, our patient underwent unilateral nephrectomy and insertion of a peritoneal dialysis catheter followed by another unilateral nephrectomy. One month later, she underwent an ABO‐compatible living‐donor kidney transplantation at the age of 4 years.Conclusions: Our patient is a neonatal‐onset ILNEB patient who survived for more than 2 years and underwent successful kidney transplantation.


  • Open Access

    Investigation of TSH receptor blocking antibodies in childhood-onset atrophic autoimmune thyroiditis

    by Keisuke Nagasaki, Akie Nakamura, Takeru Yamauchi, Hotaka Kamasaki, Yosuke Hara, Junko Kanno, Satomi Koyama, Yoshiaki Ohtsu, Ikuko Takahashi, Shigeru Suzuki, et al.

    Atrophic autoimmune thyroiditis (AAT) is a type of autoimmune hypothyroidism without goiter. TSH receptor-blocking antibodies (TSBAb) are involved in its etiology in adults. Reportedly, this disease is extremely rare in children. In this study, we aimed to investigate the prevalence of TSBAb during AAT onset in children using a commercially available cell-based bioassay TSAb kit. We conducted a multicenter retrospective observational study. We collected data of patients with AAT who were < 15 yr old, enrolled in a collaborative research group, and diagnosed since July 2003. AAT was defined as acquired autoimmune hypothyroidism without thyroid enlargement. Eighteen patients (including 15 females) whose TSH receptor antibody (TRAb) or TSBAb levels were measured within a year from the initial visit were included. The median age at diagnosis was 9.3 years, and the estimated time between onset and diagnosis was 2.6 yr. The positive rate for either TSBAb or TRAb was 38.8% (95% confidence interval: 18.3–59.5%). There were no significant differences in age, the estimated time between onset and diagnosis, and FT4 levels at diagnosis between the TSBAb-positive and -negative groups. Unlike previous reports, we showed that the prevalence of TSBAb-positivity in childhood-onset AATs is not rare, as in adults.


  • Open Access

    Temple syndrome in a patient with variably methylated CpGs at the primary MEG3/DLK1:IG-DMR and severely hypomethylated CpGs at the secondary MEG3:TSS-DMR

    by Masayo Kagami, Atsuhiro Yanagisawa, Miyuki Ota, Kentaro Matsuoka, Akie Nakamura, Keiko Matsubara, Kazuhiko Nakabayashi, Shuji Takada, Maki Fukami, Tsutomu Ogata

    The human chromosome 14q32.2 imprinted region harbors the primary MEG3/DLK1:IG-differentially methylated region (DMR) and secondary MEG3:TSS-DMR. The MEG3:TSS-DMR can remain unmethylated only in the presence of unmethylated MEG3/DLK1:IG-DMR in somatic tissues, but not in the placenta, because of a hierarchical regulation of the methylation pattern between the two DMRs. We performed molecular studies in a 4-year-old Japanese girl with Temple syndrome (TS14). Pyrosequencing analysis showed extremely low methylation levels of five CpGs at the MEG3:TSS-DMR and grossly normal methylation levels of four CpGs at the MEG3/DLK1:IG-DMR in leukocytes. HumanMethylation450 BeadChip confirmed marked hypomethylation of the MEG3:TSS-DMR and revealed multilocus imprinting disturbance (MLID) including mild hypomethylation of the H19/IGF2:IG-DMR and mild hypermethylation of the GNAS A/B:TSS-DMR in leukocytes. Bisulfite sequencing showed markedly hypomethylated CpGs at the MEG3:TSS-DMR and irregularly and non-differentially methylated CpGs at the MEG3/DLK1:IG-DMR in leukocytes and apparently normal methylation patterns of the two DMRs in the placenta. Maternal uniparental disomy 14 and a deletion involving this imprinted region were excluded. Such a methylation pattern of the MEG3/DLK1:IG-DMR has not been reported in patients with TS14. It may be possible that a certain degree of irregular hypomethylation at the MEG3/DLK1:IG-DMR has prevented methylation of the MEG3:TSS-DMR in somatic tissues and that a hypermethylation type MLID has occurred at the MEG3/DLK1:IG-DMR to yield the apparently normal methylation pattern in the placenta.